LB Pharmaceuticals (LBRX) Stock Price

LB Pharmaceuticals Price

NYSE·CLOSED
43.01
​
Market closed

Analysts set a median price target of 45.00 USD, implying 4.6% above the current price. Of 18 analysts, 16 rate the stock a buy — an overall Buy consensus.

LB Pharmaceuticals stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LB Pharmaceuticals business model & stock analysis

LB Pharmaceuticals Inc generates revenue through the development and commercialization of its lead product candidate, LB-102, a Phase III-ready oral small molecule for acute schizophrenia treatment. The company focuses on neuropsychiatric diseases, targeting schizophrenia and bipolar depression with its clinical-stage pipeline. LB-102, positioned as the first benzamide antipsychotic drug potentially approved in the U.S., is developed alongside a long-acting injectable formulation to address patient compliance issues in chronic conditions. The firm’s revenue model relies on future drug approvals and sales, with no current commercial products generating income. The company’s primary customers are patients with schizophrenia and bipolar depression, who require treatment for acute psychotic episodes and long-term management. Healthcare providers and institutions prescribing LB-102 for neuropsychiatric disorders form the direct purchasing segment. The firm’s pipeline includes LB-102, targeting the U.S. market, and its LAI formulation, designed to improve adherence in chronic neuropsychiatric care. No other products or revenue streams are mentioned in the business description. LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company with no existing commercial products. Its revenue will depend on successful clinical trials, regulatory approvals, and subsequent sales of LB-102 and its LAI formulation. The company’s business model centers on developing therapies for unmet needs in neuropsychiatric disorders, with no current revenue sources disclosed beyond future potential.

Frequently asked questions about LB Pharmaceuticals

Analysts currently set an average price target of 49.71 USD for the LB Pharmaceuticals stock (median: 45.00 USD), implying +15.6 % versus the latest price. The consensus is based on 18 analyst ratings.

18 analysts currently rate the LB Pharmaceuticals stock: 16 recommend buying, 2 holding and 0 selling.

Converted at the current exchange rate, the LB Pharmaceuticals share trades at 38.99 EUR (43.01 USD).

The revenue cannot currently be calculated for LB Pharmaceuticals.

The expected profit of LB Pharmaceuticals is -138.50 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of LB Pharmaceuticals is currently -7.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the LB Pharmaceuticals stock.

The P/S cannot be calculated for LB Pharmaceuticals currently.

The Eulerpool Quality Score for LB Pharmaceuticals is 2/10.

The ISIN of LB Pharmaceuticals is US50180M1080. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of LB Pharmaceuticals is LBRX. The ticker symbol is used to trade LB Pharmaceuticals shares on the stock exchange.

Fair ValueTerminal
39.14 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website lbpharma.us
Currency
USD
Initial public offering
Sep 11, 2025
ISIN
US50180M1080
Cusip
50180M108
Market capitalization
1.09 B USDSmall Cap
52-Week Range
PEG
4.32
P/E ratio
P/Ee 2026
-7.86
P/Ee 2027
-8.38
P/Ee 2028
-9.15
P/Ee 2029
-9.50
P/Ee 2030
-13.29
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
3.61
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-8.34 %
Last updated Nov 16, 2026, 3:41 AM

LB Pharmaceuticals Peer Group